Application of CD54 in Diagnosing Bone Marrow Involvement by Using Flow Cytometry in Patients with Diffuse Large B-cell Lymphoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Sep 10

PMID 34503477

Citations 1

Authors

Wei Wang

Yan Li

Xavier Rivera Rivera

Linjun Zhao

Di Mei

Wenqing Hu

Bin Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Flow cytometry plays a key role in detecting bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL). To improve its detection sensitivity, we need to explore novel markers. In this study, we detected the expression CD54 on lymphoma cells in BM specimens from DLBCL patients and clarified its diagnostic significance in BM involvement by DLBCL.

Methods: We collected BM specimens from 76 patients with DLBCL (germinal center B-cell (GCB) = 25, non-GCB = 51) and 10 control patients without lymphoma. We detected and compared the expression of CD54 on lymphoma cells and normal mature B cells by using 10-color panels.

Results: Normal plasma cells expressed a higher level of CD54 as compared with hematogones (p < 0.05) and normal mature B cells (p < 0.05). Among 76 patients, 23 of them (GCB = 12, non-GCB = 11) had BM involvement. Lymphoma B cells from 12 cases (GBC = 4, non-GCB = 8) expressed a higher level of CD54 compared to normal mature B cells (p < 0.05). Additionally, lymphoma cells of the non-GCB subtype frequently expressed a higher level of CD54 in comparison to the GCB subtype (p < 0.05). And the high expression of CD54 was not related to plasmacytoid differentiation.

Conclusion: Aberrant expression of CD54 on lymphoma cells is frequently seen in patients' BM specimens involved by DLBCL, especially in the non-GCB subtype. CD54 could be used as a new marker to gate on lymphoma cells and improve the detection sensitivity of BM involvement in patients with DLBCL.

Citing Articles

Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens.

Wang W, Li Y, Ali H, Zhao L, Mei D, Hu W BMC Cancer. 2021; 21(1):1315.

PMID: 34879826 PMC: 8653582. DOI: 10.1186/s12885-021-09061-3.

References

Campbell J, Matthews J, Seymour J, Wolf M, Juneja S . Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Ann Oncol. 2003; 14(2):273-6. DOI: 10.1093/annonc/mdg055. View

Greenbaum U, Levi I, Madmoni O, Lior Y, Al-Athamen K, Perry Z . The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry. Leuk Lymphoma. 2019; 60(10):2477-2482. DOI: 10.1080/10428194.2019.1587755. View

Kuhlman P, Moy V, Lollo B, Brian A . The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation. J Immunol. 1991; 146(6):1773-82. View

Brudno J, Tadmor T, Pittaluga S, Nicolae A, Polliack A, Dunleavy K . Discordant bone marrow involvement in non-Hodgkin lymphoma. Blood. 2015; 127(8):965-70. PMC: 4768431. DOI: 10.1182/blood-2015-06-651968. View

Boyd A, Wawryk S, Burns G, Fecondo J . Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci U S A. 1988; 85(9):3095-9. PMC: 280150. DOI: 10.1073/pnas.85.9.3095. View

Campbell J, Seymour J, Matthews J, Wolf M, Stone J, Juneja S . The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006; 76(6):473-80. DOI: 10.1111/j.1600-0609.2006.00644.x. View

Terol M, Lopez-Guillermo A, Bosch F, Villamor N, Cid M, Rozman C . Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J Clin Oncol. 1998; 16(1):35-40. DOI: 10.1200/JCO.1998.16.1.35. View

Tomita N, Takeuchi K, Hyo R, Hashimoto C, Takemura S, Taguchi J . Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry. Acta Haematol. 2009; 121(4):196-201. DOI: 10.1159/000220332. View

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

10.

Ohmoto A, Maeshima A, Taniguchi H, Tanioka K, Makita S, Kitahara H . Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry. Leuk Lymphoma. 2015; 56(12):3301-5. DOI: 10.3109/10428194.2015.1034702. View

11.

Schniederjan S, Li S, Saxe D, Lechowicz M, Lee K, Terry P . A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. Am J Clin Pathol. 2010; 133(5):718-26. DOI: 10.1309/AJCP0XQDGKFR0HTW. View

12.

Seegmiller A, Hsi E, Craig F . The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms. Cytometry B Clin Cytom. 2018; 96(1):20-29. DOI: 10.1002/cyto.b.21756. View

13.

Chantepie S, Cornet E, Salaun V, Reman O . Hematogones: an overview. Leuk Res. 2013; 37(11):1404-11. DOI: 10.1016/j.leukres.2013.07.024. View

14.

Onciu M, Berrak S, Medeiros L, Katz R, Huh Y . Discrepancies in the immunophenotype of lymphoma cells in samples obtained simultaneously from different anatomic sites. Am J Clin Pathol. 2002; 117(4):644-50. DOI: 10.1309/urtd-7md9-u8n1-c60q. View

15.

Hodges G, Lenhardt T, Cotelingam J . Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol. 1994; 101(3):305-11. DOI: 10.1093/ajcp/101.3.305. View

16.

Duggan P, Easton D, Luider J, Auer I . Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry: correlation with morphology. Cancer. 2000; 88(4):894-9. View

17.

Kussick S, Kalnoski M, Braziel R, Wood B . Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol. 2004; 121(4):464-72. DOI: 10.1309/4EJ8-T3R2-ERKQ-61WH. View

18.

Cardoso C, Auat M, Santos-Pirath I, Rudolf-Oliveira R, da Silva J, Lange B . The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry. Cytometry B Clin Cytom. 2017; 94(3):451-458. DOI: 10.1002/cyto.b.21533. View

19.

Chung R, Lai R, Wei P, Lee J, Hanson J, Belch A . Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007; 110(4):1278-82. DOI: 10.1182/blood-2007-01-070300. View

20.

Reid S, Yang S, Brown R, Kabani K, Aklilu E, Ho P . Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol. 2010; 32(6 Pt 1):e190-6. DOI: 10.1111/j.1751-553X.2010.01222.x. View